7.54
+0.36(+5.01%)
Currency In USD
| Previous Close | 7.18 |
| Open | 7.18 |
| Day High | 7.75 |
| Day Low | 7.54 |
| 52-Week High | 13.79 |
| 52-Week Low | 4.56 |
| Volume | 1,697 |
| Average Volume | 7,443 |
| Market Cap | 29.91M |
| PE | -2.64 |
| EPS | -2.86 |
| Moving Average 50 Days | 7.95 |
| Moving Average 200 Days | 7.85 |
| Change | 0.36 |
If you invested $1000 in MiNK Therapeutics, Inc. (INKT) since IPO date, it would be worth $62.83 as of May 17, 2025 at a share price of $7.54. Whereas If you bought $1000 worth of MiNK Therapeutics, Inc. (INKT) shares 3 years ago, it would be worth $584.5 as of May 17, 2025 at a share price of $7.54.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report
GlobeNewswire Inc.
May 05, 2025 4:30 PM GMT
NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNK
MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report
GlobeNewswire Inc.
Mar 04, 2025 12:30 PM GMT
NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (i
MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting
GlobeNewswire Inc.
Feb 24, 2025 1:30 PM GMT
Addition of AgenT-797 with Checkpoint Inhibitors, BOT/BAL, and Chemotherapy Demonstrates Robust Immune Activation, Offering Potential to Overcome Refractory Gastric CancersNEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: